Topoisomerase II inhibitors.
Hande
Kenneth R
KR
Vanderbilt/Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA. Kenneth.Hande@vanderbilt.edu
D018943:Anthracyclines / Q000627:therapeutic use / Q000633:toxicity; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D004249:DNA Damage / Q000235:genetics; D004791:Enzyme Inhibitors / Q000627:therapeutic use* / Q000633:toxicity; D005047:Etoposide / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D059005:Topoisomerase II Inhibitors
D018943:Anthracyclines; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D005047:Etoposide